1. Generics Bulletin
  2. >>Preview

What’s Next? Five Things To Look Out For In March

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for March 2025.

What's Next Image
Norstella/Citeline

Amgen will look to kick off March by launching its Bkemv (eculizumab-aeeb) US Food and Drug Administration-approved biosimilar to AstraZeneca’s Soliris (eculizumab) – the first biosimilar to the paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment set to reach the US, via its 2020 settlement with the originator.

The California-based biotech will enjoy a non-exclusive, royalty-free, license under US patents and patent applications related to eculizumab and various...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Preview

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

What’s Next? Five Things To Look Out For In April

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for April 2025.

What’s Next? Five Things To Look Out For In March

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for March 2025.

What’s Next? Five Things To Look Out For In February

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for February 2025.

More from Biosimilars

Sandoz Leads Charge With First US Denosumab Launch

 
• By Dave Wallace

Competition to Amgen’s Prolia and Xgeva denosumab brands has hit the US market, with Sandoz taking the lead by launching its interchangeable Jubbonti and Wyost biosimilars.

‘Obsessive’ Teva Aims For $800m Biosimilar Sales By 2027

 
• By Dean Rudge

Teva says it is now in the “accelerate growth” phase of its strategic roadmap, with global biosimilar launches set to help the firm achieve its goals.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By Dave Wallace

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.